BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 16984974)

  • 1. A novel domain on HLA-DRbeta chain regulates the chaperone role of the invariant chain.
    Neumann J; Koch N
    J Cell Sci; 2006 Oct; 119(Pt 20):4207-14. PubMed ID: 16984974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A three-amino-acid-long HLA-DRbeta cytoplasmic tail is sufficient to overcome ER retention of invariant-chain p35.
    Khalil H; Brunet A; Thibodeau J
    J Cell Sci; 2005 Oct; 118(Pt 20):4679-87. PubMed ID: 16188937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assembly of major histocompatibility complex class II subunits with invariant chain.
    Neumann J; Koch N
    FEBS Lett; 2005 Nov; 579(27):6055-9. PubMed ID: 16242130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of aberrant association of DM with MHC class II subunits in the absence of invariant chain.
    Neumann J; König A; Koch N
    Int Immunol; 2007 Jan; 19(1):31-9. PubMed ID: 17105964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Class II-associated invariant chain peptide-independent binding of invariant chain to class II MHC molecules.
    Thayer WP; Ignatowicz L; Weber DA; Jensen PE
    J Immunol; 1999 Feb; 162(3):1502-9. PubMed ID: 9973407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of MHC class II molecules with the invariant chain: role of the invariant chain (81-90) region.
    Stumptner P; Benaroch P
    EMBO J; 1997 Oct; 16(19):5807-18. PubMed ID: 9312039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variation in HLA-DM expression influences conversion of MHC class II alpha beta:class II-associated invariant chain peptide complexes to mature peptide-bound class II alpha beta dimers in a normal B cell line.
    Ramachandra L; Kovats S; Eastman S; Rudensky AY
    J Immunol; 1996 Mar; 156(6):2196 - 2204. PubMed ID: 8690909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a sequence that mediates promiscuous binding of invariant chain to MHC class II allotypes.
    Siebenkotten IM; Carstens C; Koch N
    J Immunol; 1998 Apr; 160(7):3355-62. PubMed ID: 9531295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquisition of peptides by MHC class II polypeptides in the absence of the invariant chain.
    Hitzel C; van Endert P; Koch N
    J Immunol; 1995 Feb; 154(3):1048-56. PubMed ID: 7822782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel family of human leukocyte antigen class II receptors may have its origin in archaic human species.
    Temme S; Zacharias M; Neumann J; Wohlfromm S; König A; Temme N; Springer S; Trowsdale J; Koch N
    J Biol Chem; 2014 Jan; 289(2):639-53. PubMed ID: 24214983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3.
    Ghosh P; Amaya M; Mellins E; Wiley DC
    Nature; 1995 Nov; 378(6556):457-62. PubMed ID: 7477400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CLIP-region mediated interaction of Invariant chain with MHC class I molecules.
    Powis SJ
    FEBS Lett; 2006 May; 580(13):3112-6. PubMed ID: 16678175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Editing of the HLA-DR-peptide repertoire by HLA-DM.
    Kropshofer H; Vogt AB; Moldenhauer G; Hammer J; Blum JS; Hämmerling GJ
    EMBO J; 1996 Nov; 15(22):6144-54. PubMed ID: 8947036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Invariant chain transmembrane domain trimerization: a step in MHC class II assembly.
    Dixon AM; Stanley BJ; Matthews EE; Dawson JP; Engelman DM
    Biochemistry; 2006 Apr; 45(16):5228-34. PubMed ID: 16618111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interference of distinct invariant chain regions with superantigen contact area and antigenic peptide binding groove of HLA-DR.
    Vogt AB; Stern LJ; Amshoff C; Dobberstein B; Hämmerling GJ; Kropshofer H
    J Immunol; 1995 Nov; 155(10):4757-65. PubMed ID: 7594477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mediation by HLA-DM of dissociation of peptides from HLA-DR.
    Sloan VS; Cameron P; Porter G; Gammon M; Amaya M; Mellins E; Zaller DM
    Nature; 1995 Jun; 375(6534):802-6. PubMed ID: 7596415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invariant chain association with MHC class I: preference for HLA class I/beta 2-microglobulin heterodimers, specificity, and influence of the MHC peptide-binding groove.
    Vigna JL; Smith KD; Lutz CT
    J Immunol; 1996 Nov; 157(10):4503-10. PubMed ID: 8906828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant intermolecular disulfide bonding in a mutant HLA-DM molecule: implications for assembly, maturation, and function.
    Busch R; Doebele RC; von Scheven E; Fahrni J; Mellins ED
    J Immunol; 1998 Jan; 160(2):734-43. PubMed ID: 9551909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diminished class II-associated Ii peptide binding to the juvenile dermatomyositis HLA-DQ alpha 1*0501/DQ beta 1*0301 molecule.
    Reed AM; Collins EJ; Shock LP; Klapper DG; Frelinger JA
    J Immunol; 1997 Dec; 159(12):6260-5. PubMed ID: 9550430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreas carcinoma antigen fused to invariant chain elicits T-cell response and tumor growth inhibition.
    Nagaraj S; Neumann J; Winzen B; Frank S; Ziske C; Sievers E; Koch N; Schmidt-Wolf IG
    Pancreas; 2008 Oct; 37(3):321-7. PubMed ID: 18815556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.